Corient Private Wealth LLC Acquires 10,895 Shares of GSK plc (NYSE:GSK)

Corient Private Wealth LLC grew its holdings in GSK plc (NYSE:GSK) by 12.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,344 shares of the pharmaceutical company’s stock after acquiring an additional 10,895 shares during the period. Corient Private Wealth LLC’s holdings in GSK were worth $3,258,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Dorsey & Whitney Trust CO LLC boosted its holdings in shares of GSK by 2.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after buying an additional 278 shares during the period. Sunbelt Securities Inc. boosted its holdings in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Rehmann Capital Advisory Group boosted its holdings in shares of GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after buying an additional 332 shares during the period. GC Wealth Management RIA LLC boosted its holdings in shares of GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after buying an additional 353 shares during the period. Finally, Jacobi Capital Management LLC boosted its holdings in shares of GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock worth $352,000 after buying an additional 389 shares during the period. 15.74% of the stock is owned by institutional investors.

GSK Trading Down 0.5 %

Shares of GSK stock opened at $39.22 on Friday. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93. The stock has a market cap of $81.18 billion, a price-to-earnings ratio of 24.67, a P/E/G ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm has a fifty day moving average of $36.66 and a 200-day moving average of $36.92.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, equities research analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.01%. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is currently 98.74%.

Wall Street Analysts Forecast Growth

GSK has been the subject of several research analyst reports. Morgan Stanley initiated coverage on shares of GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.